QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-optinose-maintains-9-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Neutral and maintains $9 price tar...

 piper-sandler-downgrades-optinose-to-neutral-lowers-price-target-to-9

Piper Sandler analyst David Amsellem downgrades OptiNose (NASDAQ:OPTN) from Overweight to Neutral and lowers the price targe...

 hc-wainwright--co-downgrades-optinose-to-neutral-lowers-price-target-to-9

HC Wainwright & Co. analyst Matthew Caufield downgrades OptiNose (NASDAQ:OPTN) from Buy to Neutral and lowers the price ...

 lake-street-downgrades-optinose-to-hold-lowers-price-target-to-9

Lake Street analyst Thomas Flaten downgrades OptiNose (NASDAQ:OPTN) from Buy to Hold and lowers the price target from $17 to...

 optinose-stock-is-soaring-today-whats-going-on

OptiNose Inc (NASDAQ:OPTN) shares are trading higher Thursday after Paratek Pharmaceuticals announced a deal to acquire the com...

 us-stocks-likely-to-open-lower-after-fed-decision-any-pullback-in-equities-offers-an-opportunity-says-expert

U.S. stock futures rose on Thursday following the Federal Open Market Committee's decision on Wednesday calling inflation &...

 reported-earlier-paratek-pharmaceuticals-to-acquire-optinose-in-deal-worth-up-to-330m-including-9-cash-and-potential-5share-in-future-milestones

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion fo...

 hc-wainwright--co-maintains-buy-on-optinose-raises-price-target-to-18

HC Wainwright & Co. analyst Matthew Caufield maintains OptiNose (NASDAQ:OPTN) with a Buy and raises the price target fro...

 optinose-plans-to-effect-1-for-15-reverse-stock-split-at-500-pm-eastern-standard-time-on-december-30-2024

Beginning with the opening of trading on December 31, 2024, Optinose's common stock will trade on the Nasdaq Global Select ...

 piper-sandler-maintains-overweight-on-optinose-lowers-price-target-to-1

Piper Sandler analyst David Amsellem maintains OptiNose (NASDAQ:OPTN) with a Overweight and lowers the price target from $3 ...

 hc-wainwright--co-reiterates-buy-on-optinose-maintains-5-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Buy and maintains $5 price target.

 optinose-expects-2024-xhance-net-revenues-of-75m-79m-compared-to-prior-guidance-of-85m-90m-with-average-net-revenue-per-prescription-to-be-approximately-270-versus-prior-guidance-to-exceed-250

Financial GuidanceXHANCE Net Revenue The Company expects XHANCE net revenues for the full year of 2024 to be between $75.0 to $...

 optinose-q3-2024-gaap-eps-000-beats-005-estimate-sales-2044m-miss-2300m-estimate

OptiNose (NASDAQ:OPTN) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.05) by 1...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION